Bilibili Inc vs Cronos Group Inc — how do they compare? Bilibili Inc trades at $17.75 (market cap $7.71B), while Cronos Group Inc trades at $3.08 (market cap $1.11B). The key difference: Bilibili Inc is far larger — about 6.9× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.
| BILI | CRON | |
|---|---|---|
Market Cap | $7.71B | $1.11B |
Sector | Media | Health |
52-Week High | $35.92 | $3.27 |
52-Week Low | $15.96 | $2.30 |
Enterprise Value | $5.54B | $310.67M |
Signals from Pluang's Aura AI — not financial advice
Bilibili (BILI) trades at $18.74, up 0.48% with neutral technical signals. The company reported strong Q1 2026 earnings of $0.19 per share, beating estimates, and maintains solid profitability with a 4.58% net margin. Recent news highlights a new $300 million share repurchase program and upcoming Q2 2026 results on August 27, 2026. Technical indicators show mixed signals with RSI neutral but moving averages bullish.
Bilibili presents a compelling investment case with consistent earnings beats and strong analyst support (83% buy ratings). However, risks include competitive pressures in China's video platform market and reliance on advertising revenue growth. The upcoming Q2 earnings report will be crucial for validating the company's monetization strategy and user engagement metrics.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →